Aktuellt
SENASTE
Redeye leaves a comment following Magle’s recent announcement of a directed share issue of approximately SEK26.6m. While we did not anticipate the company to perform another share issue, the capital raised will enable Magle to advance key clinical studies, enhance its product portfolio, and position the company to deliver greater long-term value to shareholders. We reiterate our base case valuation to SEK48.
LÄS MER
